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Supplementary magnesium in traumatic 
brain injury: where do we go from here?
David James Davies
A key aspect of providing good quality 
care to patients who have sustained 
moderate to severe traumatic brain injury 
(TBI) is taking on the heavy burden of 
electrolyte homeostasis for which their 
neuroaxis is temporarily unable to 
manage. Typically, the first focus of the 
neurosurgeon and neurointensivist is close 
regulation of sodium and potassium 
delivery and excretion due to the imme-
diate and overwhelming influence of the 
neuroendocrine axis on these,1 2 together 
with the natural compartmental fluid shift 
that will accompany such changes and 
their effects on TBI outcome.3 4 However, 
much less clearly defined and understood 
is the influence of actively manipulating 
magnesium homeostasis in such cases. 
Current practice tends towards the avoid-
ance of significant depletion; however, 
magnesium has a number of well-rec-
ognised interactions with major 
neurotransmitters such as glutamate, and 
through them has been identified as modu-
lating the neuroinflammatory response 
through multiple in vivo models.5–7 From 
these observations, a considerable body of 
preclinical and pilot clinical evidence as to 
the positive effects of supplementary 
magnesium within the context of major 
neurological trauma has been assem-
bled.8 9 Despite this promising data, unfa-
vourable outcomes reported by key 
clinical studies10 suggest the translational 
relationship between experimental obser-
vations and clinical application is complex 
and not fully understood. Therefore, as 
yet the routine therapeutic use of magne-
sium supplementation is not within the 
current mainstream of TBI treatment.11 12 
In response to the lack of clarity on this 
issue, Lyons et al13 present a summary of 
the current evidence regarding the use 
of supplemental magnesium within this 
context. Within the field of TBI research, 
there is a strong sense of feeling that 
magnesium represents a likely potential 
target for disease modifying therapy despite 
(as yet) the absence of a formal reference 
to support this. Lyons et al astutely point 
out that the fact that within this field many 
practitioners consider the case closed for 
supplemental magnesium (sulfate) due to a 
large (greater than 400 patient) randomised 
placebo controlled trial undertaken by 
Temkin et al,10 in which no benefit or 
indeed a slight adverse effect was observed 
in patients selected for treatment. This trial 
very much represents the fulcrum of judge-
ment regarding this topic. However, the 
strength of evidence in preclinical models is 
very difficult to ignore and therefore stim-
ulates an appetite to explore the potential 
oversights within what is considered the 
definitive literature. It is worth mentioning 
that a similar index of suspicion exists as to 
the utility of magnesium in the treatment of 
aneurysmal subarachnoid haemorrhage. In 
this situation also, a robust body of preclin-
ical evidence has yet to translate into a 
measurable clinical benefit.14
A number of factors must be consid-
ered when attempting to offer an expla-
nation to this lack of translatability. First, 
the dose relationship between potential 
beneficial effect, no effect and harm is 
likely to be complex and nuanced due to 
the significant influence the administra-
tion of magnesium has on multiple body 
systems (especially cardiovascular). There-
fore, until a better understanding of the 
in vivo distribution and effects of specific 
dose regimes of magnesium are known 
(potentially through a mechanistic cere-
bral microdialysis study), any trial designed 
will potentially not hit the theoretical dose 
‘sweet spot’ that may be required. TBI as 
a disease is very heterogeneous (although 
certain mechanisms of tissue injury will be 
common to most patterns of injury e.g cyto-
skeletal disruption, and loss of electrolytic 
membrane integrity), and therefore any 
future investigations into the potential role 
for supplemental magnesium may require 
more specific target stratification. Focal and 
semifocal injury patters such as those mani-
fested by local contusion, or direct tissue 
disruption due to mechanical impingement, 
may have significantly different responses 
and requirements (with regard to electro-
lyte physiology) than a broadly diffuse and 
global insult such as those in large external 
hemispherical mass effect or diffuse axonal 
injury. Such careful injury phenotype selec-
tion may provide a clear answer to where 
any beneficial role for magnesium may lie 
and in whom.
Such patient selection and stratification 
may not necessarily be via radiological/
anatomical methods; biomarkers specifi-
cally characterising the immediate immune 
response to traumatic insult15 (particu-
larly considering the inferred relevance 
of neuroinflammation to magnesium) 
may play a significant role in such exper-
imental design. A key aspect (some may 
say a requirement) of in vivo (animal) TBI 
modelling is the homogeneity of the neuro-
axial insult delivery.16 Each animal receives 
a carefully orchestrated impact, modelling 
with a range of insult mechanisms may elude 
to which ‘type’ of injury response better to 
which therapy. It should be mentioned here 
however that there are a number of different 
models of both focal and diffuse moderate/
severe TBI in vivo, but investigations using 
them usually do so in isolation. This type 
of injury modelling may be considered as 
not entirely representative of the extremely 
variable/mixed system pattern of energy 
absorption seen in clinical TBI practice. It 
is therefore possible that these characteris-
tics of preclinical modelling, together with 
inadequate patient selection stratification 
and injury phenotype identification may be 
contributing to the lack of beneficial effect 
seen in translational studies into the use of 
magnesium (and numerous other disease 
modifying agents for use in TBI).
The review by Lyons et al within this issue 
represents a positive first step in revisiting 
this (potentially) suboptimally investigated 
topic. A better understanding of the current 
evidence, and an appreciation of the limita-
tions of the studies, which represent it, is 
critical in order to proceed with better-de-
signed investigations. TBI represents the 
most complex pattern of injury, in the most 
complex organ in the body17 (would this 
author had been so fortunate as to coin that 
phrase), and such needs the most intricate 
and comprehensive investigations to make 
meaningful progress.
Collaborators Antonio Belli, Kamal Yakoub, Valantina 
DiPietro.
Contributors I am the sole author and compiler of 
this editorial document.
Funding The authors have not declared a specific 
grant for this research from any funding agency in the 
public, commercial or not-for-profit sectors. 
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; 
internally peer reviewed.
Correspondence to Mr  David James Davies, Trauma 
Neurosurgery, University Hospitals Birmingham, 
Birmingham B15 2TH, UK;  d. j. davies. 1@ bham. ac. uk
Editorial
 o
n
 16 August 2018 by guest. Protected by copyright.
http://jramc.bmj.com/
J R Arm
y M
ed Corps: first published as 10.1136/jramc-2018-000985 on 18 June 2018. Downloaded from 
2 Davies DJ. J R Army Med Corps Month 2018 Vol 0 No 0
Editorial
Open access This is an open access article distributed 
in accordance with the Creative Commons Attribution 
Non Commercial (CC BY-NC 4.0) license, which permits 
others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on 
different terms, provided the original work is properly 
cited and the use is non-commercial. See: http:// 
creativecommons. org/ licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless 
otherwise stated in the text of the article) 2018. All 
rights reserved. No commercial use is permitted unless 
otherwise expressly granted.
To cite Davies DJ. J R Army Med Corps Epub ahead of 
print: [please include Day Month Year]. doi:10.1136/
jramc-2018-000985
Accepted 15 May 2018
J R Army Med Corps 2018;0:1–2.
doi:10.1136/jramc-2018-000985
RefeRences
 1 Maas AI, Stocchetti N, Bullock R. Moderate and 
severe traumatic brain injury in adults. Lancet Neurol 
2008;7:728–41.
 2 Van Beek JG, Mushkudiani NA, Steyerberg EW, et al. 
Prognostic value of admission laboratory parameters in 
traumatic brain injury: results from the IMPACT study. J 
Neurotrauma 2007;24:315–28.
 3 Donkin JJ, Vink R. Mechanisms of cerebral edema in 
traumatic brain injury: therapeutic developments. Curr 
Opin Neurol 2010;23:293–9.
 4 Earle SA, Proctor KG, Patel MB, et al. Ubiquitin 
reduces fluid shifts after traumatic brain injury. Surgery 
2005;138:431–8.
 5 Burd I, Breen K, Friedman A, et al. Magnesium sulfate 
reduces inflammation-associated brain injury in fetal 
mice. Am J Obstet Gynecol 2010;202:292.e1–292.e9.
 6 Muir KW. Glutamate-based therapeutic approaches: 
clinical trials with NMDA antagonists. Curr Opin 
Pharmacol 2006;6:53–60.
 7 Dorsett CR, McGuire JL, DePasquale EA, et 
al. Glutamate neurotransmission in rodent 
models of traumatic brain injury. J Neurotrauma 
2017;34:263–72.
 8 Vink R, O’Connor CA, Nimmo AJ, et al. Magnesium 
attenuates persistent functional deficits following 
diffuse traumatic brain injury in rats. Neurosci Lett 
2003;336:41–4.
 9 Bareyre FM, Saatman KE, Raghupathi R, et al. 
Postinjury treatment with magnesium chloride 
attenuates cortical damage after traumatic brain injury 
in rats. J Neurotrauma 2000;17:1029–39.
 10 Temkin NR, Anderson GD, Winn HR, et al. Magnesium 
sulfate for neuroprotection after traumatic brain 
injury: a randomised controlled trial. Lancet Neurol 
2007;6:29–38.
 11 Marehbian J, Muehlschlegel S, Edlow BL, et al. Medical 
management of the severe traumatic brain injury 
patient. Neurocrit Care 2017;27:430–46.
 12 Carney N, Totten AM, O’Reilly C, et al. Guidelines for 
the management of severe traumatic brain injury, 
fourth edition. Neurosurgery 2017;80:6–15.
 13 Lyons MWH, Blackshaw WJ. Does magnesium sulfate 
have a role in the management of severe traumatic 
brain injury in civilian and military populations? A 
systematic review and meta-analysis. J R Army Med 
Corps 2018. doi: 10.1136/jramc-2018-000916. [Epub 
ahead of print].
 14 Dorhout Mees SM, Algra A, Wong GK, et al. Early 
magnesium treatment after aneurysmal subarachnoid 
hemorrhage: individual patient data meta-analysis. 
Stroke 2015;46:3190–3.
 15 Hazeldine J, Naumann DN, Toman E, et al. Prehospital 
immune responses and development of multiple 
organ dysfunction syndrome following traumatic 
injury: A prospective cohort study. PLoS Med 
2017;14:e1002338.
 16 Xiong Y, Mahmood A, Chopp M. Animal models 
of traumatic brain injury. Nat Rev Neurosci 
2013;14:128–42.
 17 Wheble JL, Menon DK. TBI-the most complex  
disease in the most complex organ: the CENTER-
TBI trial-a commentary. J R Army Med Corps 
2016;162:87–9.
 o
n
 16 August 2018 by guest. Protected by copyright.
http://jramc.bmj.com/
J R Arm
y M
ed Corps: first published as 10.1136/jramc-2018-000985 on 18 June 2018. Downloaded from 
